Reviewed October 30, 2026 · Research-use information
the short answer
There is no established BPC-157 drug-interaction list for dogs. No controlled canine trials have been completed, and the FDA says safety information is limited. That does not mean interactions are impossible; it means they are unstudied. Tell your vet about every prescription, supplement, and recent injection, especially NSAIDs, steroids, immunosuppressants, or blood thinners. Never stop a prescribed medicine to try a peptide.
| Medication group | Why it needs a conversation | What to do |
|---|---|---|
| NSAIDs and steroids | GI, kidney, and bleeding risks already need monitoring; no BPC-157 interaction data | Tell the vet; do not stop on your own |
| Immunosuppressants | Immune effects and product impurities are unstudied | Vet review before starting |
| Anticoagulants or bleeding risk | Preclinical blood-flow findings do not establish a bleeding interaction | Vet review; report bruising or bleeding |
| Other injectables or vaccines | No combination data; timing is a clinical judgment | Ask the vet about spacing |
| Supplements | Labels vary; hidden ingredients are possible | Bring every label |
Not an interaction list. These are medication groups that deserve a specific vet conversation.
Why there is no interaction list
An interaction list is built from controlled studies, pharmacokinetic data, and adverse-event reporting in the species being treated. BPC-157 has none of that in dogs. The human evidence is also thin: a 2026 systematic review found three small studies with 30 participants, judged poor quality, with very low certainty. That is not a database a veterinarian can use to clear a combination. It is a reason to treat every medication question as open.
What the FDA and reviews actually say
The FDA's compounding safety page says BPC-157 may pose an immunogenicity risk and may have complexities with peptide-related impurities and ingredient characterization. It also says the agency has no, or only limited, safety information. A 2026 orthopaedic review says validated dosing, pharmacokinetic, and long-term safety data are lacking. None of that names a specific drug interaction. It describes a gap, not a green light.
Medication groups that deserve a specific conversation
A veterinarian is likely to want more detail for dogs on NSAIDs, steroids, immunosuppressants, anticoagulants or antiplatelet drugs, and other injectable products. That is not because a BPC-157 interaction has been proven. It is because those drugs already carry monitoring needs, and adding an unstudied peptide makes the picture less clear. The vet may adjust monitoring, change timing, or decide not to combine them at all. That is a medical judgment, not a product-page answer.
Do not stop a prescribed medicine
Stopping Librela, an NSAID, a steroid, or any other prescribed drug to try a peptide can cause a pain flare or other harm. The prescribed plan belongs to your vet. A research peptide is not a cure, and it is not a substitute for that plan. If you want to add one, ask about the whole plan first: what stays, what changes, what is monitored, and what would make them stop. A pen is not a reason to abandon pain control or a diagnosis.
How to prepare for the vet call
Bring the full medication list, including doses, times, and who prescribed each one. Add supplements, recent vaccines, and any injection or procedure in the last month. Bring the product label and batch certificate for the peptide. Ask three questions: Is this combination studied in dogs? What should I monitor? What would make you stop? If the answer is 'we do not know,' that is useful information, not a rejection.
If a reaction happens
Stop the peptide and call your vet if you see vomiting, diarrhea, lethargy, appetite loss, hives, facial swelling, trouble breathing, collapse, or a change in gait. Do not give another click to test the theory. Tell the vet what was given, how much, and when. A reaction is not proof of causation, but it is a reason for an exam. Report suspected adverse events to the FDA's veterinary adverse-event system as well.
What we do not claim
- We do not claim this is a complete BPC-157 interaction list.
- We do not claim a specific drug is safe or unsafe to combine with BPC-157.
- We do not claim human interaction data apply to dogs.
- We do not claim stopping a prescribed medicine is safe without your vet.
Sources
Reviewed October 30, 2026. These are the sources we used for this page. Dollar figures, where present, are estimates from the named source, not quotes.
- FDA: Certain Bulk Drug Substances for Use in CompoundingBPC-157 immunogenicity and peptide-impurity concerns; content current April 22, 2026.
- PubMed: Human evidence for BPC-157 (2026 systematic review)Three small human studies, poor methodological quality, very low certainty.
- PubMed: Investigational peptides in orthopaedic practice (2026)Validated dosing, pharmacokinetic, and long-term safety data are lacking.
- AVMA: Your pet's medicationsTell your vet about every medication and supplement; human doses are not dog doses.
Questions owners ask
Does BPC-157 interact with NSAIDs in dogs?
There is no controlled canine data on the combination. NSAIDs already need monitoring for GI, kidney, and bleeding effects. Tell your vet before combining them, and do not stop the NSAID on your own.
Can I give BPC-157 with Librela?
There is no controlled canine data on that combination. Ask your vet. Do not stop or change Librela without them; it is a prescribed pain medication.
Does BPC-157 interact with blood thinners?
No canine interaction study exists. Preclinical blood-flow findings do not establish a bleeding interaction, but a dog with a bleeding disorder or on an anticoagulant needs a vet review before any injectable peptide.
What should I bring to the vet?
Every medication and supplement, with doses and timing, plus the product label, batch certificate, and any recent diagnoses or surgeries. Ask what to monitor and what would make them stop.